PortalPublikationenRelapse to prior autograft and chronic graft-versus-host dis...

Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.

Standard

Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. / Kröger, Nicolaus-Martin; Perez-Simon, Jose A; Myint, Han; Klingemann, Hans; Shimoni, Avichai; Nagler, Arnon; Martino, Rodrigo; Alegre, Adrian; Tomas, Jose F; Schwerdtfeger, Rainer; Kiehl, Michael; Fauser, Axel; Sayer, Herbert Gottfried; Leon, Angel; Beyer, Jörg; Zabelina, Tatjana; Ayuketang Ayuk, Francis; Miguel, San; Jesus, F; Brand, Ronald; Zander, Axel.

in: BIOL BLOOD MARROW TR, Jahrgang 10, Nr. 10, 10, 2004, S. 698-708.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kröger, N-M, Perez-Simon, JA, Myint, H, Klingemann, H, Shimoni, A, Nagler, A, Martino, R, Alegre, A, Tomas, JF, Schwerdtfeger, R, Kiehl, M, Fauser, A, Sayer, HG, Leon, A, Beyer, J, Zabelina, T, Ayuketang Ayuk, F, Miguel, S, Jesus, F, Brand, R & Zander, A 2004, 'Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.', BIOL BLOOD MARROW TR, Jg. 10, Nr. 10, 10, S. 698-708. <http://www.ncbi.nlm.nih.gov/pubmed/15389436?dopt=Citation>

APA

Kröger, N-M., Perez-Simon, J. A., Myint, H., Klingemann, H., Shimoni, A., Nagler, A., Martino, R., Alegre, A., Tomas, J. F., Schwerdtfeger, R., Kiehl, M., Fauser, A., Sayer, H. G., Leon, A., Beyer, J., Zabelina, T., Ayuketang Ayuk, F., Miguel, S., Jesus, F., ... Zander, A. (2004). Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. BIOL BLOOD MARROW TR, 10(10), 698-708. [10]. http://www.ncbi.nlm.nih.gov/pubmed/15389436?dopt=Citation

Vancouver

Kröger N-M, Perez-Simon JA, Myint H, Klingemann H, Shimoni A, Nagler A et al. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. BIOL BLOOD MARROW TR. 2004;10(10):698-708. 10.

Bibtex

@article{c3fb4a3a39584f849a99bc8eae8d839f,
title = "Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.",
abstract = "We evaluated prognostic factors of melphalan/fludarabine-based dose-reduced allografts in patients with multiple myeloma. From 1998 to 2002, 120 patients with multiple myeloma were treated with melphalan/fludarabine followed by allogeneic stem cell transplantation. The cumulative risk at 1 year for treatment-related mortality (TRM) was 18% (95% confidence interval [CI], 12%-28%). In a multivariate analysis, relapse after prior high-dose chemotherapy was the most significant risk factor for TRM (hazard ratio [HR], 2.80; 95% CI, 1.16-6.74; P =.02), relapse (HR, 4.14; 95% CI, 2.04-8.38; P",
author = "Nicolaus-Martin Kr{\"o}ger and Perez-Simon, {Jose A} and Han Myint and Hans Klingemann and Avichai Shimoni and Arnon Nagler and Rodrigo Martino and Adrian Alegre and Tomas, {Jose F} and Rainer Schwerdtfeger and Michael Kiehl and Axel Fauser and Sayer, {Herbert Gottfried} and Angel Leon and J{\"o}rg Beyer and Tatjana Zabelina and {Ayuketang Ayuk}, Francis and San Miguel and F Jesus and Ronald Brand and Axel Zander",
year = "2004",
language = "Deutsch",
volume = "10",
pages = "698--708",
journal = "BIOL BLOOD MARROW TR",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "10",

}

RIS

TY - JOUR

T1 - Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.

AU - Kröger, Nicolaus-Martin

AU - Perez-Simon, Jose A

AU - Myint, Han

AU - Klingemann, Hans

AU - Shimoni, Avichai

AU - Nagler, Arnon

AU - Martino, Rodrigo

AU - Alegre, Adrian

AU - Tomas, Jose F

AU - Schwerdtfeger, Rainer

AU - Kiehl, Michael

AU - Fauser, Axel

AU - Sayer, Herbert Gottfried

AU - Leon, Angel

AU - Beyer, Jörg

AU - Zabelina, Tatjana

AU - Ayuketang Ayuk, Francis

AU - Miguel, San

AU - Jesus, F

AU - Brand, Ronald

AU - Zander, Axel

PY - 2004

Y1 - 2004

N2 - We evaluated prognostic factors of melphalan/fludarabine-based dose-reduced allografts in patients with multiple myeloma. From 1998 to 2002, 120 patients with multiple myeloma were treated with melphalan/fludarabine followed by allogeneic stem cell transplantation. The cumulative risk at 1 year for treatment-related mortality (TRM) was 18% (95% confidence interval [CI], 12%-28%). In a multivariate analysis, relapse after prior high-dose chemotherapy was the most significant risk factor for TRM (hazard ratio [HR], 2.80; 95% CI, 1.16-6.74; P =.02), relapse (HR, 4.14; 95% CI, 2.04-8.38; P

AB - We evaluated prognostic factors of melphalan/fludarabine-based dose-reduced allografts in patients with multiple myeloma. From 1998 to 2002, 120 patients with multiple myeloma were treated with melphalan/fludarabine followed by allogeneic stem cell transplantation. The cumulative risk at 1 year for treatment-related mortality (TRM) was 18% (95% confidence interval [CI], 12%-28%). In a multivariate analysis, relapse after prior high-dose chemotherapy was the most significant risk factor for TRM (hazard ratio [HR], 2.80; 95% CI, 1.16-6.74; P =.02), relapse (HR, 4.14; 95% CI, 2.04-8.38; P

M3 - SCORING: Zeitschriftenaufsatz

VL - 10

SP - 698

EP - 708

JO - BIOL BLOOD MARROW TR

JF - BIOL BLOOD MARROW TR

SN - 1083-8791

IS - 10

M1 - 10

ER -